Chiral control
US-2024229026-A1 · Jul 11, 2024 · US
Derivatives of sobetirome
US9701650B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9701650-B2 |
| Application number | US-201615048672-A |
| Country | US |
| Kind code | B2 |
| Filing date | Feb 19, 2016 |
| Priority date | Feb 20, 2015 |
| Publication date | Jul 11, 2017 |
| Grant date | Jul 11, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound with the structure: or any pharmaceutically acceptable salt thereof, where R1 is an alkylamino. 2. The compound of claim 1 where R1 is substituted alkylamine, cycloalkylamino, or substituted cycloalkylamino. 3. The compound of claim 1 wherein R1 is ethylamino, ethyl(N,N,N)-trimethylamino, ethylmorpholinyl, ethyl(N,N)-dimethylamino, 3-(N-methyl)azetidinyl, 4-pyrrolidinyl, 3-pyrrolidinyl, 2,2-dimethylethylamino, 3-(3-trifluoromethyl)azetidinyl, 2-pyrrolidinyl, 2-methylethylamino, 2-trifluoromethylamino, N-methyl-ethylomino, 1-methyl-(N,N)dimethylethylamino, 1-methyl-2-imazodinylethylamino; 1-methyl-2-keto-ethylamino, 1-isopropyl-ethylamino, and 1-isopropyi-N-methyl-ethylamino. 4. The compound of claim 3 wherein R1 is 2-methylethylamino further comprising R and S enantiomers. 5. The compound of claim 3 with the structure: 6. The compound of claim 5 wherein the compound is a halide salt. 7. The compound of claim 3 with the structure selected from: 8. A pharmaceutical composition comprising an effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carriers.
Assignees
Inventors
Classifications
Oxygen atoms · CPC title
attached in position 3 or 5 · CPC title
attached in position 4 · CPC title
having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups (peptides C07K) · CPC title
having the esterifying carboxyl radicals attached to acyclic carbon atoms · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9701650B2 cover?
- Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.
- Who is the assignee on this patent?
- Univ Oregon Health & Science
- What technology area does this patent fall under?
- Primary CPC classification C07D295/088. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jul 11 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).